Last reviewed · How we verify
MEDI-551 30 MG-IV — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
MEDI-551 30 MG-IV (MEDI-551 30 MG-IV) — MedImmune LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MEDI-551 30 MG-IV TARGET | MEDI-551 30 MG-IV | MedImmune LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MEDI-551 30 MG-IV CI watch — RSS
- MEDI-551 30 MG-IV CI watch — Atom
- MEDI-551 30 MG-IV CI watch — JSON
- MEDI-551 30 MG-IV alone — RSS
Cite this brief
Drug Landscape (2026). MEDI-551 30 MG-IV — Competitive Intelligence Brief. https://druglandscape.com/ci/medi-551-30-mg-iv. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab